Novel lecithin: cholesterol acyltransferase-based therapeutic approaches.
Curr Opin Lipidol
; 31(2): 71-79, 2020 04.
Article
en En
| MEDLINE
| ID: mdl-32073411
ABSTRACT
PURPOSE OF REVIEW To review recent lecithincholesterol acyltransferas (LCAT)-based therapeutic approaches for atherosclerosis, acute coronary syndrome, and LCAT deficiency disorders. RECENT FINDINGS:
A wide variety of approaches to using LCAT as a novel therapeutic target have been proposed. Enzyme replacement therapy with recombinant human LCAT is the most clinically advanced therapy for atherosclerosis and familial LCAT deficiency (FLD), with Phase I and Phase 2A clinical trials recently completed. Liver-directed LCAT gene therapy and engineered cell therapies are also another promising approach. Peptide and small molecule activators have shown efficacy in early-stage preclinical studies. Finally, lifestyle modifications, such as fat-restricted diets, cessation of cigarette smoking, and a diet rich in antioxidants may potentially suppress lipoprotein abnormalities in FLD patients and help preserve LCAT activity and renal function but have not been adequately tested.SUMMARY:
Preclinical and early-stage clinical trials demonstrate the promise of novel LCAT therapies as HDL-raising agents that may be used to treat not only FLD but potentially also atherosclerosis and other disorders with low or dysfunctional HDL.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fosfatidilcolina-Esterol O-Aciltransferasa
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Lipidol
Asunto de la revista:
BIOQUIMICA
Año:
2020
Tipo del documento:
Article